Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Observatory, G16.68 New Main Building, 7925 Cape Town, South Africa.
J Antimicrob Chemother. 2022 Feb 2;77(2):277-278. doi: 10.1093/jac/dkab426.
COVID-19 has highlighted the worldwide inequities in access to the tools needed to tackle the pandemic. The same is the case for antibiotic resistance (ABR), which is projected to cause far greater devastation. The truth is that unless we tackle the burden of infectious diseases in low- and middle-income countries (LMICs), we will not impact ABR worldwide. Despite valiant efforts we have largely failed to address antibiotic conservation. We have directed millions of dollars into developing new antibiotics and surveillance systems and mostly ignored interventions such as infection prevention. Insufficient resources are dedicated to interventions such as sanitation and clean water, vaccination and changes in agricultural practice to reduce reliance on antimicrobials. Large-scale public health interventions are required. Funding mechanisms must be found to support LMICs in making these changes. Action is required at the highest levels.
COVID-19 凸显了全球在获得应对大流行病所需工具方面的不平等。抗生素耐药性（ABR）也是如此，预计它将造成更大的破坏。事实是，除非我们解决中低收入国家（LMICs）的传染病负担，否则我们将无法在全球范围内对抗 ABR。尽管我们做出了巨大努力，但在抗生素的保护方面基本上还是失败了。我们已经投入了数百万美元用于开发新的抗生素和监测系统，而大部分干预措施，如感染预防，都被忽视了。用于改善环境卫生和清洁水、疫苗接种以及改变农业实践以减少对抗生素的依赖等干预措施的资源不足。需要采取大规模的公共卫生干预措施。必须找到供资机制来支持 LMICs 进行这些变革。最高层需要采取行动。
